All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Blogs » BioWorld MedTech Perspectives » Momma said there'd be days like this: Heartware pauses trial again

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular

Momma said there'd be days like this: Heartware pauses trial again

Jan. 28, 2016
By Omar Ford
No Comments

 

HeartThe mood was pretty somber going into Heartware’s (Framingham, Mass.) breakout session during the 34th annual J.P.Morgan Healthcare conference. But why wouldn’t it be? It’s not everyday that a med-tech CEO has to discuss halting a European trial on one of its most promising technologies.

But that’s exactly what Doug Godshall, Heartware president/CEO did. Godshall, who took the leadership position of Heartware in 2006, delivered the bad news across a sea of somewhat disenchanted faces during the conference. He did a great job, but honestly, is there ever a “good way” to deliver bad news?

You see, Godshall revealed there were thrombus complications with MVAD that occurred in late December, causing the company to once again pause its CE-mark trial. Heartware's MVAD pump is a continuous axial flow pump. The MVAD trial is a prospective, non-randomized, single-arm study, that began in July. The trial will be implant patients with the MVAD pump via sternotomy or thoracotomy, with a primary endpoint of survival at six months. The thrombus complications that occurred during the trial are from sustained suction that stem from Qpulse, a software algorithm that periodically regulates the speed of MVAD to promote aortic valve opening during left ventricular support.

And it should be pointed out that those December complications – well they come on the heels of Heartware pausing the MVAD trial back in September. The study was initially paused to allow for a minor circuit board fix for the device's external controller. Now the company is in the process of exploring a few options. It can tinker with the algorithm; or it can do a redesign of the MVAD. There is no real concrete timetable for this but Godshall said it would take a minimum of 18 months to get back into the clinic if a design change was needed for the device.

What makes this pill even harder to swallow is that it’s chief rival in the space, Thoratec Corp. (Pleasanton, Calif.) is being integrated quite nicely after it was acquired by St. Jude Medical Inc. (Rochester, Minn.) for $3.4 billion. During St. Jude’s presentation at J.P. Morgan, it’s CEO Michael Rousseau spoke up about the Thoratec acquisition and spoke about its reasons to go for Thoratec.

"We saw a technology and we liked it," Rosseau said of Thoratec’s Heartmate. "We thought Heartmate data looked really good. "We thought there were a lot of questions marks in Heartware’s [data]. We think the Thoratec acquisition was the right decision."

Ouch.

The only bright spot for Heartware is that it is on track in its bid to secure a destination therapy (DT) indication for the HVAD system based on positive trends observed in the ENDURANCE2 trial. Heartware said it could submit to the FDA for approval in mid-2016. That could be a tremendous boost to the company, and help offset some of the bad news surrounding the MVAD trial.

 

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing